| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | Replimune Group Inc: Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) | 180 | GlobeNewswire (Europe) | SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies... ► Artikel lesen | |
| 07.04. | Regeneron Pharmaceuticals, Inc.: Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma | 175 | GlobeNewswire (Europe) | TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2... ► Artikel lesen | |
| 07.04. | Esperion Therapeutics, Inc.: Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity | 200 | GlobeNewswire (Europe) | - Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo - - NEXLETOL Demonstrated Clinical Benefit in Historically... ► Artikel lesen | |
| 07.04. | BridgeBio Pharma, Inc.: BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 137 | GlobeNewswire (Europe) | - In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression... ► Artikel lesen | |
| 07.04. | iTeos Therapeutics Inc.: iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 | 776 | GlobeNewswire (Europe) | WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development... ► Artikel lesen | |
| 07.04. | BioNTech SE: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer | 626 | GlobeNewswire (Europe) | Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses... ► Artikel lesen | |
| 07.04. | McWhorter Foundation: C.K. McWhorter & Single Family Office to Pioneer Integration of Quantum Computing Technologies Across All Luxury Asset Sectors Harnessing the Speed of Formula 1 | 414 | GlobeNewswire (Europe) | NEW YORK, April 07, 2024 (GLOBE NEWSWIRE) -- With an expansive vision that transcends traditional boundaries, C.K. McWhorter, the strategic mind behind the McWhorter Family Office, announces a groundbreaking... ► Artikel lesen | |
| 07.04. | Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer | 754 | GlobeNewswire (Europe) | SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 1.682 |
| NEL | 1.667 |
| SUPER MICRO COMPUTER | 1.656 |
| NVIDIA | 1.649 |
| TUI | 1.484 |
| BAYER | 1.336 |
| RHEINMETALL | 1.000 |
| RENK GROUP | 930 |
| PROSIEBENSAT.1 | 912 |
| VOLKSWAGEN | 735 |
| AMAZON | 699 |
| PALANTIR TECHNOLOGIES | 698 |
| TESLA | 687 |
| MICROSTRATEGY | 636 |
| DEUTSCHE BANK | 585 |
| PLUG POWER | 571 |
| BASF | 565 |
| BYD | 557 |
| THYSSENKRUPP | 542 |
| COMMERZBANK | 535 |
| AIXTRON SE | 532 |
| SAP | 507 |
| MERCEDES-BENZ | 506 |
| ALLIANZ | 493 |
| DEUTSCHE TELEKOM | 473 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
